Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

1.480 -0.090 (-5.73%)
Official Closing Price Updated: 8:00 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,792,539
Open 1.550
Bid (Size) 1.500 (600)
Ask (Size) 1.550 (100)
Prev. Close 1.570
Today's Range 1.460 - 1.580
52wk Range 0.3651 - 2.090
Shares Outstanding 174,986,671
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics Issues Letter to Stockholders
From Lineage Cell Therapeutics, Inc.
Via Business Wire

Performance

YTD
-9.8%
-9.8%
1 Month
-11.4%
-11.4%
3 Month
-22.9%
-22.9%
6 Month
+50.2%
+50.2%
1 Year
+136.2%
+136.2%

More News

Read More
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
A Peek at Lineage Cell Therapeutics's Future Earnings ↗
Via Benzinga
News headline image
Lineage Cell Therapeutics Inc (NYSEARCA:LCTX) Reports Q3 2025 Earnings: Revenue Beat Overshadowed by Wider-Than-Expected Loss ↗
Via Chartmill
News headline image
Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
5 Analysts Assess Lineage Cell Therapeutics: What You Need To Know ↗
Via Benzinga
News headline image
Lineage Cell Therapeutics to Present at September 2025 Investor Conferences
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Via Benzinga
News headline image
Lineage Cell Revenue Doubles in Q2 ↗
Via The Motley Fool
News headline image
Lineage Cell Therapeutics Inc. (NYSEARCA:LCTX) Reports Q2 2025 Revenue Beat but Wider Loss ↗
Via Chartmill
News headline image
Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For August 12, 2025 ↗
Via Benzinga
News headline image
Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Two Biotech Stocks Poised For Big Moves On Monday ↗
Via Benzinga
News headline image
Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For May 13, 2025 ↗
Via Benzinga

Frequently Asked Questions

Is Lineage Cell Therapeutics, Inc. Common Stock publicly traded?
Yes, Lineage Cell Therapeutics, Inc. Common Stock is publicly traded.
What exchange does Lineage Cell Therapeutics, Inc. Common Stock trade on?
Lineage Cell Therapeutics, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Lineage Cell Therapeutics, Inc. Common Stock?
The ticker symbol for Lineage Cell Therapeutics, Inc. Common Stock is LCTX on the New York Stock Exchange
What is the current price of Lineage Cell Therapeutics, Inc. Common Stock?
The current price of Lineage Cell Therapeutics, Inc. Common Stock is 1.480
When was Lineage Cell Therapeutics, Inc. Common Stock last traded?
The last trade of Lineage Cell Therapeutics, Inc. Common Stock was at 01/30/26 08:00 PM ET
What is the market capitalization of Lineage Cell Therapeutics, Inc. Common Stock?
The market capitalization of Lineage Cell Therapeutics, Inc. Common Stock is 258.98M
How many shares of Lineage Cell Therapeutics, Inc. Common Stock are outstanding?
Lineage Cell Therapeutics, Inc. Common Stock has 259M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.